EUVIMEDEUVIMED entdecken
Crossref

The Effect of Denosumab on Risk for Emergently Treated Hypocalcemia by Stage of Chronic Kidney Disease

Steven T Bird, Kate Gelperin, Elizabeth R Smith iD, Tae Hyun Jung, Hai Lyu iD, Aliza Thompson, Olivia Easley, Kushal B Naik iD, Yueqin Zhao, Rekha Kambhampati, Michael Wernecke iD, Ali Niak iD und 4 weitere

Annals of Internal Medicine · 2025-01 · 178 (1) · 29-38

DOI: 10.7326/m24-0013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Internal Medicine, 2025-01. Verfasst von Steven T Bird und 15 weiteren Autor:innen. Beteiligte Einrichtung: Office of Pharmacovigilance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland (S.…. Hauptthemen laut MEDLINE: Denosumab, Hypocalcemia, Bone Density Conservation Agents, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: There is a paucity of data on treatment of osteoporosis in patients with advanced chronic kidney disease (CKD). OBJECTIVE: To assess the risk for emergently treated hypocalcemia with denosumab by stage of CKD and presence of CKD-mineral and bone disorder (CKD-MBD). DESIGN: Target trial emulation. SETTING: Medicare fee-for-service data with prescription drug coverage, 2012 to 2020. PARTICIPANTS: Female patients aged 65 years or older initiating denosumab, oral bisphosphonates, or intravenous (IV) bisphosphonates for osteoporosis. MEASUREMENTS: Hospital and emergency department admissions (that is, emergent care) for hypocalcemia were assessed in the first 12 treatment weeks. Inverse probability of treatment weighted cumulative incidence and weighted risk differences (RDs) were calculated. RESULTS: A total of 361 453 patients treated with denosumab, 829 044 treated with oral bisphosphonates, and 160 413 treated with IV bisphosphonates were identified. Risk for emergently treated hypocalcemia with denosumab versus oral bisphosphonates increased with worsening CKD stage (P < 0.001), with greatest risk among dialysis-dependent (DD) patients (3.01% vs. 0.00%; RD, 3.01% [95% CI, 2.27% to 3.77%]) and non-dialysis-dependent (NDD) patients with CKD stages 4 and 5 (0.57% vs. 0.03%; RD, 0.54% [CI, 0.41% to 0.68%]). Among patients with stages 4 and 5 CKD (NDD + DD), denosumab had a greater risk for emergently treated hypocalcemia versus oral bisphosphonates in those with CKD-MBD (1.53% vs. 0.02%; RD, 1.51% [CI, 1.21% to 1.78%]) than in those without CKD-MBD (0.22% vs. 0.03%; RD, 0.19% [CI, 0.08% to 0.31%]). Denosumab also showed increased risk compared with IV bisphosphonates. LIMITATION: Generalizability to men and non-Medicare populations. CONCLUSION: Risk for emergently treated hypocalcemia with denosumab increased with worsening CKD stage and was highest in DD patients and those with CKD-MBD. PRIMARY FUNDING SOURCE: U.S. Food and Drug Administration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DenosumabHypocalcemiaBone Density Conservation AgentsRenal Insufficiency, ChronicOsteoporosisHumansFemaleAgedAged, 80 and overDiphosphonatesUnited StatesMedicare

Substanzen

DenosumabBone Density Conservation AgentsDiphosphonates

Autor:innen und Institutionen

  • Office of Pharmacovigilance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland (S.T.B., K.G., A.N., D.J.G.).
  • Acumen, Burlingame, California (E.R.S., H.L., K.B.N., M.W., Y.C.).
  • Division of Biometrics 7, Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland (T.H.J., Y.Z.).
  • Division of Cardiology and Nephrology, Office of Cardiology, Hematology, Endocrinology, and Nephrology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland (A.T., R.K.).
  • Division of General Endocrinology, Office of Cardiology, Hematology, Endocrinology, and Nephrology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland (O.E., M.Z.).
  • Centers for Medicare & Medicaid Services, Washington, DC (J.A.K.).

ORCID-Profile: Elizabeth R Smith, Hai Lyu, Kushal B Naik, Michael Wernecke, Ali Niak, Yoganand Chillarige, David J Graham

Zitieren

APA

Bird, S. T., Gelperin, K., Smith, E. R., Jung, T. H., Lyu, H., Thompson, A., Easley, O., Naik, K. B., Zhao, Y., Kambhampati, R., Wernecke, M., Niak, A., Zemskova, M., Chillarige, Y., Kelman, J. A., & Graham, D. J. (2025). The Effect of Denosumab on Risk for Emergently Treated Hypocalcemia by Stage of Chronic Kidney Disease. Annals of Internal Medicine, 178(1), 29-38. https://doi.org/10.7326/m24-0013

Vancouver

Bird ST, Gelperin K, Smith ER, Jung TH, Lyu H, Thompson A, et al. The Effect of Denosumab on Risk for Emergently Treated Hypocalcemia by Stage of Chronic Kidney Disease. Annals of Internal Medicine. 2025;178(1):29-38. doi:10.7326/m24-0013

BibTeX
@article{Bird2025,
  author = {Bird, Steven T and Gelperin, Kate and Smith, Elizabeth R and Jung, Tae Hyun and Lyu, Hai and Thompson, Aliza and Easley, Olivia and Naik, Kushal B and Zhao, Yueqin and Kambhampati, Rekha and Wernecke, Michael and Niak, Ali and Zemskova, Marina and Chillarige, Yoganand and Kelman, Jeffrey A and Graham, David J},
  title = {The Effect of Denosumab on Risk for Emergently Treated Hypocalcemia by Stage of Chronic Kidney Disease},
  journal = {Annals of Internal Medicine},
  year = {2025},
  volume = {178},
  number = {1},
  pages = {29--38},
  doi = {10.7326/m24-0013}
}
Kostenlos starten →